AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
22.9 C
New York
Friday, October 16, 2026

Tag: cancer

Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

DA NANG, Vietnam, June 18, 2026 /PRNewswire/ -- Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought...

Health and Wellness Market Size to Hit $12.9 Trillion by 2031 Growing at a CAGR of 10.9%: Allied Market Research

Prevention and Curing Conditions On The Rise, Strong Demand for Beauty & Personal Care Products, Booming Wellness Tourism and Digital Health Nowadays to Accelerate the Growth of...

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with...

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage...

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

$GRAL Fraud Notice: GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

SHINE and newcleo Partner to Advance U.S. Spent Nuclear Fuel Recycling

JANESVILLE, Wis. and PARIS, June 17, 2026 (GLOBE NEWSWIRE) -- SHINE, a fusion energy company with a platform expanding into nuclear fuel recycling, and newcleo, a developer of advanced nuclear reactors and fuel, today announced an agreement to collaborate on advancing innovative technologies for the recycling of used nuclear fuel.

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing...

Steer Health Wins 2026 Hearst Health Prize

$125,000 in Hearst Health Prize awards recognize Steer Health and finalist Dana-Farber Cancer Institute for innovative uses of data science to improve health outcomesLOS...

Silexion Therapeutics to Attend BIO International Convention 2026

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that Company management, including the Company’s Chief Executive Officer, Ilan Hadar, and the Company’s Chief Financial Officer, Mirit Horenshtein-Hadar, will attend the 2026 BIO International Convention, taking place on June 22-25 in San Diego, CA.  

My Derma Dream MyoGlow Examined 2026 – Why Is the MyoGlow Arm Device Getting So Much Attention Across the United States?

Miami, Florida, June 16, 2026 (GLOBE NEWSWIRE) --

There is a quiet conversation happening in fitting rooms, group texts, and medical offices all over the country that rarely surfaces publicly. It is about arms. More specifically, it is about the moment a woman picks up a sleeveless top, holds it against herself in the mirror, and puts it back on the rack. Not because the top is the wrong color or cut. Because she does not want her arms on display.

SkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare Providers

SkinVision Pro connects AI-powered skin health assessments directly to medical practices, giving doctors structured information before the consultation begins. AMSTERDAM, June 16, 2026 /PRNewswire/...

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer